Item 2.02. Results of Operations and Financial Condition
On January 26, 2021, Catalyst Biosciences, Inc. (the "Company"), filed with the
Securities and Exchange Commission (the "SEC"), a preliminary prospectus
supplement (the "Preliminary Prospectus") pursuant to Rule 424(b) under the
Securities Act of 1933, as amended (the "Securities Act"), related to the
issuance and sale of shares of its common stock in an underwritten public
offering (the "Offering"). In the Preliminary Prospectus, the Company disclosed
that it expects to report that the Company had cash, cash equivalents, and
investments of approximately $81.9 million as of December 31, 2020. This amount,
is based solely upon information available to it as of the date of this Current
Report on Form 8-K, is preliminary, has not been audited and is subject to
change pending completion of the Company's audited consolidated financial
statements for the year ended December 31, 2020. Additional information and
disclosures would be required for a more complete understanding of the Company's
financial position and results of operations as of December 31, 2020. The
Company expects to complete its audited consolidated financial statements for
the year ended December 31, 2020 subsequent to the completion of the Offering.
It is possible that the Company or its independent registered public accounting
firm may identify items that require them to make adjustments to the preliminary
estimated cash, cash equivalents and investments balance set forth above and
those changes could be material.
The information in this Item 2.02 shall not be deemed to be "filed" for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that section or Sections 11 and 12(a)(2) of the
Securities Act. The information contained in this Item 2.02 shall not be
incorporated by reference into any registration statement or other document
filed by the Company with the SEC, whether made before or after the date of this
Current Report on Form 8-K, regardless of any general incorporation language in
such filing (or any reference to this Current Report on Form 8-K generally),
except as shall be expressly set forth by specific reference in such filing.
Item 8.01 Other Events
On January 26, 2021, the Company issued a press release announcing the Offering.
A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit
No. Description
99.1 Press release issued by Catalyst Biosciences, Inc., dated January
26, 2021
104 Cover Page Interactive Data File (formatted as Inline XBRL)
2
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses